Loading organizations...
Loading organizations...
Wynnefield Capital is an investment management firm specializing in value investing within the US small-cap equity market. The firm rigorously identifies situations with specific company or industry catalysts, employing a deep research-driven approach. Its strategy targets smaller public enterprises poised for revaluation based on anticipated corporate events or sector-specific developments.
Co-founded in November 1992 by Nelson Obus and Joshua Landes, Wynnefield Capital leveraged their senior research equity experience from Lazard Freres & Co. Their insight focused on the potential within the small-cap sector, applying a disciplined, catalyst-focused value methodology to unlock shareholder value.
The firm serves sophisticated investors seeking specialized exposure to the small-capitalization universe. Wynnefield Capital’s vision involves consistently applying fundamental research to exploit market inefficiencies. They strive to generate robust returns by investing where a definable catalyst is expected to drive substantial share revaluation.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 9, 2023 | Lifecore Biomedical | $38.8M Series A | 22NW Fund, Legion Partners | 325 Capital, Cove Street Partners |
| Nov 25, 2022 | Lifecore Biomedical | $5.0M Other Equity | Wynnefield Capital | — |